Health & Environmental Research Online (HERO)


Print Feedback Export to File
6117187 
Journal Article 
Cytogenetic and immunohistochemical biomarker profiling of therapy-relevant factors in salivary gland carcinomas 
Lemound, J; Schenk, M; Keller, G; Stucki-Koch, A; Witting, S; Kreipe, H; Hussein, K 
2016 
Yes 
Journal of Oral Pathology and Medicine
ISSN: 1600-0714
EISSN: 16000714 
45 
9 
655-663 
English 
27037970 
WOS:000385713700004 
OBJECTIVES: There is currently no established algorithm for the molecular profiling of therapy-relevant defects in salivary gland carcinomas (SGC). HER2 overexpression in a subfraction of SGC and low frequencies of EGFR mutations are known. Here, we established receptor and cell signalling profiles of 17 therapy-relevant factors and propose a molecular diagnostic algorithm for SGC.

MATERIALS AND METHODS: Formalin-fixed and paraffin-embedded tissue samples from SGC (n = 38) were analysed with immunohistochemistry and fluorescence in situ hybridisation (FISH).

RESULTS: Two or more expressed receptors and/or receptor gene amplification were detectable in eight of 38 (21%) tumours: HER2 3+/AR 1+, HER3 gene amplification/AR 1+/EGFR 1+, ER 3+/AR 1+, EGFR 2+/PR 1+ and EGFR 2+/PR 1+/AR 1+. No FGFR1-3, MET, ALK1, ROS1, RET, BRAF nor VEGFA defects were detectable, and ERCC1 was not overexpressed. No PD1+ tumour-infiltrating T cells were detectable.

CONCLUSION: Personalised therapy of patients with salivary gland carcinomas should include HER2 and EGFR signalling testing and, in negative cases, evaluation of rare potential target molecules. ERCC1 and PD1 do not appear to be reliable markers for the decision for or against chemotherapy or immunotherapy, respectively.